Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Dulaglutide

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

Company n/r · Phase 3 · Completed · Enrollment 159

NCT07820111

ArmPopulationDoseWeeksEstimandWeight change
obese , non diabetic ,recieve dulaglutideObese Diabetics; Obese Non Diabeticn/r24n/rn/r
obese , non diabetic ,receive SEMAGLUTIDEObese Diabetics; Obese Non Diabeticn/r24n/rn/r
obese , non diabetic ,receive TIRAZEPETIDEObese Diabetics; Obese Non Diabeticn/r24n/rn/r
obese , diabetic ,recieve dulaglutideObese Diabetics; Obese Non Diabeticn/r24n/rn/r
obese , diabetic ,receive SEMAGLUTIDEObese Diabetics; Obese Non Diabeticn/r24n/rn/r
obese , diabetic ,receive TIRAZEPETIDEObese Diabetics; Obese Non Diabeticn/r24n/rn/r